Study wrapper · #348
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.
Editor's note
This is an independent re-analysis of the two pivotal Phase 3 bremelanotide (PT-141) trials, drawing on the FDA New Drug Application data — a higher-quality vantage than the published papers alone. Its findings are pointed: the author reports that most protocol-listed outcomes went unreported while 15 unlisted secondary measures were presented, that reporting departed from CONSORT standards, and — most substantively — that adverse-event-driven discontinuation was far higher on bremelanotide (odds ratio ~12) and that participants effectively preferred placebo, being far less likely to both finish and opt into the open-label extension. These are serious methodological and clinical-meaningfulness critiques. As a single-author re-analysis it carries its own interpretive stance, and a published commentary disputes it, so it is not the last word. But it is grounded in regulatory data and converges with other skeptical appraisals. Weigh it as strong evidence that bremelanotide's benefit is modest and its tolerability burden real — read alongside the manufacturer-side reports.
Plain-language abstract
This meta-analysis re-examined the two main Phase 3 trials of bremelanotide (PT-141) for low sexual desire in women, using the detailed data submitted to the FDA. The author reports several problems with how the original results were published. Nearly three-quarters of the outcomes that the trial protocols said would be measured were not reported, while 15 other measures that were not pre-planned were presented instead. The reporting did not follow standard scientific guidelines, and the extra measures had no stated justification or proof they were meaningful. The author's own analysis found effects similar to the original, but also highlighted two things the original did not emphasize: far more women stopped bremelanotide because of side effects than stopped placebo (about 12 times the odds), and overall women appeared to prefer placebo — they were more likely to finish the trial and choose to continue into the follow-up study when on placebo. The author concludes the drug's small benefits, on questionable measures, suggest it is generally not useful.